Article Details

MacroGenics HER2 drug scores FDA breast cancer nod with Herceptin-topping data

Retrieved on: 2020-12-17 16:30:00

Tags for this article:

Click the tags to see associated articles and topics

MacroGenics HER2 drug scores FDA breast cancer nod with Herceptin-topping data. View article details on hiswai:

Excerpt

MacroGenics' Margenza has been approved by the FDA to treat third-line HER2-positive breast cancer after showing it could top <b>Roche's</b> Herceptin in ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up